146 related articles for article (PubMed ID: 26461819)
1. Anti-IL-23 Phase II Data for Psoriasis: A Review.
Beroukhim K; Danesh MJ; Nguyen C; Austin A; Koo J; Levin E
J Drugs Dermatol; 2015 Oct; 14(10):1093-6. PubMed ID: 26461819
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Efficacy of Tildrakizumab in the Treatment of Psoriasis.
Wytsma J; Woo TE; Parsons L
Skin Therapy Lett; 2024 May; 29(3):5-8. PubMed ID: 38781953
[TBL] [Abstract][Full Text] [Related]
3. A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis.
Campa M; Mansouri B; Warren R; Menter A
Dermatol Ther (Heidelb); 2016 Mar; 6(1):1-12. PubMed ID: 26714681
[TBL] [Abstract][Full Text] [Related]
4. Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis.
Amin M; Darji K; No DJ; Wu JJ
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1627-1632. PubMed ID: 28667777
[TBL] [Abstract][Full Text] [Related]
5. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
Zhuang Y; Calderon C; Marciniak SJ; Bouman-Thio E; Szapary P; Yang TY; Schantz A; Davis HM; Zhou H; Xu Z
Eur J Clin Pharmacol; 2016 Nov; 72(11):1303-1310. PubMed ID: 27515978
[TBL] [Abstract][Full Text] [Related]
6. Anti-TNFα-therapy as an evidence-based treatment option for different clinical manifestations of psoriatic arthritis.
Köhm M; Burkhardt H; Behrens F
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S109-14. PubMed ID: 26472504
[TBL] [Abstract][Full Text] [Related]
7. Psoriasis Targeted Therapy: Characterization of Interleukin 17A Expression in Subtypes of Psoriasis.
Lee E; Zarei M; LaSenna C; Villada G; Romanelli P
J Drugs Dermatol; 2015 Oct; 14(10):1133-6. PubMed ID: 26461825
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
[TBL] [Abstract][Full Text] [Related]
9. Biologic Therapy in Psoriasis: Safety Profile.
Campanati A; Ganzetti G; Giuliodori K; Molinelli E; Offidani A
Curr Drug Saf; 2016; 11(1):4-11. PubMed ID: 26463245
[TBL] [Abstract][Full Text] [Related]
10. A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe Plaque Psoriasis.
Nawas Z; Hatch M; Ramos E; Liu M; Tong Y; Peranteau A; Tyring S
Skin Therapy Lett; 2017 Mar; 22(2):8-10. PubMed ID: 28329405
[TBL] [Abstract][Full Text] [Related]
11. European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.
Nast A; Gisondi P; Ormerod AD; Saiag P; Smith C; Spuls PI; Arenberger P; Bachelez H; Barker J; Dauden E; de Jong EM; Feist E; Jacobs A; Jobling R; Kemény L; Maccarone M; Mrowietz U; Papp KA; Paul C; Reich K; Rosumeck S; Talme T; Thio HB; van de Kerkhof P; Werner RN; Yawalkar N
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2277-94. PubMed ID: 26481193
[No Abstract] [Full Text] [Related]
12. Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis.
Johnsson HJ; McInnes IB
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S115-8. PubMed ID: 26471946
[TBL] [Abstract][Full Text] [Related]
13. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
[TBL] [Abstract][Full Text] [Related]
14. Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials.
Howell ST; Cardwell LA; Feldman SR
Ann Pharmacother; 2018 Apr; 52(4):380-387. PubMed ID: 29134822
[TBL] [Abstract][Full Text] [Related]
15. Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials.
Nakamura M; Lee K; Jeon C; Sekhon S; Afifi L; Yan D; Lee K; Bhutani T
Dermatol Ther (Heidelb); 2017 Sep; 7(3):281-292. PubMed ID: 28639011
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis.
Rouse NC; Farhangian ME; Wehausen B; Feldman SR
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):877-84. PubMed ID: 26488186
[TBL] [Abstract][Full Text] [Related]
17. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
Gooderham M; Papp K
BioDrugs; 2015 Oct; 29(5):327-39. PubMed ID: 26481941
[TBL] [Abstract][Full Text] [Related]
18. Targeting IL-23 in psoriasis: current perspectives.
Fotiadou C; Lazaridou E; Sotiriou E; Ioannides D
Psoriasis (Auckl); 2018; 8():1-5. PubMed ID: 29441315
[TBL] [Abstract][Full Text] [Related]
19. Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors.
Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Bebenek K; Kaźmierczak A
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28994166
[TBL] [Abstract][Full Text] [Related]
20. Psoriasis pathogenesis and the development of novel targeted immune therapies.
Hawkes JE; Chan TC; Krueger JG
J Allergy Clin Immunol; 2017 Sep; 140(3):645-653. PubMed ID: 28887948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
